
Design Therapeutics Inc DSGN.O:
DESIGN THERAPEUTICS ANNOUNCES START OF FRIEDREICH ATAXIA PATIENT DOSING EX-U.S. IN ITS RESTORE-FA PHASE 1/2 MULTIPLE-ASCENDING DOSE TRIAL OF DT-216P2
DESIGN THERAPEUTICS INC - FDA PLACES CLINICAL HOLD ON IND APPLICATION FOR U.S. SITES
DESIGN THERAPEUTICS INC - NO ADVERSE EVENTS REPORTED IN DT-216P2 ADMINISTRATION
DESIGN THERAPEUTICS INC - PHASE 1 SINGLE-ASCENDING DOSE TRIAL SHOWS DT-216P2 WELL-TOLERATED